[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"birth-weight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:birth-weight":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,82,104,131,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100448470","effects-of-the-mediterranean-diet-during-pregnancy-on-the-onset-of-allergies-in-the-offspring-100448470",false,"NCT05119868","Effects of the Mediterranean Diet During Pregnancy on the Onset of Allergies in the Offspring","Effects of the Mediterranean Diet During Pregnancy on the Onset of Allergies in the Offspring: a Multi-center Randomised-controlled Trial (the PREMEDI Project)","PREMEDI","Inclusion Criteria:\n\n\\- healthy women (aged 20-35 years), at first trimester of pregnancy, of at risk for atopy baby\n\nExclusion Criteria:\n\n* concomitant presence of infections;\n* concomitant presence of malignancies;\n* concomitant presence of major gastrointestinal malformations;\n* concomitant presence of immunodeficiencies;\n* concomitant presence of autoimmune diseases;\n* concomitant presence of chronic inflammatory bowel diseases;\n* concomitant presence of functional gastrointestinal disorders;\n* concomitant presence of celiac disease;\n* history of abdominal surgery with gastrointestinal resection;\n* concomitant presence of neuropsychiatric disorders;\n* concomitant presence of central nervous system disorders;\n* vegan diet;\n* twin pregnancy;\n* concomitant presence of genetic disorders;\n* concomitant presence of metabolic disorders.",true,"FEMALE","20 Years","35 Years",{"count":22,"type":23},276,"ESTIMATED","INTERVENTIONAL",[26],"NA","Allergy prevalence is increasing steadily with some describing as the \"epidemic of the twenty-first century\". Maternal diet during pregnancy has been linked to offspring allergy risk, so it represents a potential target for allergy prevention. The Mediterranean Diet (MD) is considered one of the healthiest dietary models which exerts regulatory effects on immune system, due to the synergistic and interactive combinations of nutrients. We aim to study the effects of MD in pregnancy on the onset of allergic diseases at 2 years of age in the offspring.",[29,30,31,32,33,34,35,36],"Allergies","Obesity","Gestational Complications","Gestational Weight Gain","Perinatal Condition","Birth Weight","Chronic Diseases in Children","Breast Feeding","RECRUITING","2026-02-11",{"date":40,"type":41},"2026-02-12","ACTUAL",{"date":43,"type":41},"2021-11-02",{"date":45,"type":23},"2026-03-10",{"name":47,"class":48},"Federico II University","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":18,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100557792","studying-phenotypes-of-gestational-diabetes-mellitus-in-an-asian-pregnant-cohort-100557792","NCT06542718","Studying Phenotypes of Gestational Diabetes Mellitus in an Asian Pregnant Cohort","Studying the Heterogeneity of Gestational Diabetes Mellitus: Cardio-Metabolic Alteration and Treatment Response in a Multi-Ethnic Population in Singapore (GDM-CARE)","GDM-CARE","Inclusion Criteria:\n\n* Gestational age of ≤ 13 weeks 6 days\n* Overweight and obese subjects with BMI of 23kg\u002Fm² - 24.9kg\u002Fm² and ≥ 25.0kg\u002Fm², respectively\n* Aged 21-45 years with singleton pregnancy\n* Plan to be followed up during the whole pregnancy and deliver at NUH\n* Chinese, Malay or Indian ethnicity for pregnant subject\n* Can complete questionnaires in English language\n* Willing to wear continuous glucose monitoring device at least for 7 days at each required clinic visit\n\nExclusion Criteria:\n\n* Participants who are not Singapore citizens or Singapore Permanent Residents, not intending to eventually deliver in Singapore National University Hospital and to reside in Singapore for the next 2 years\n* Have serious skin conditions (eg. eczema) that precludes wearing the sensor for 14 days\n* With history of Type 1 diabetes or Type 2 diabetes\n* With chronic preexisting life-threatening conditions including pancreatic cancer, end-stage kidney dysfunction, and psychosis\n* Unable to read or speak English","21 Years","45 Years",{"count":61,"type":23},800,"OBSERVATIONAL","Gestational diabetes mellitus (GDM) is a transient hyperglycemic condition identified during pregnancy in women without a history of chronic diabetes. Evidence indicates that GDM can lead to various adverse health outcomes, including preterm birth, progression to pre-diabetes, and type 2 diabetes after delivery in mothers. Notably, GDM is becoming increasingly prevalent among Asian pregnant women due to rising rates of overweight and obesity, as well as genetic susceptibility. Despite growing recognition of GDM, its treatment efficiency and efficacy remain poor, primarily due to its heterogeneity, which is underpinned by various pathophysiological mechanisms.\n\nTherefore, a better understanding of GDM heterogeneity can aid clinicians in providing more targeted treatment and follow-up strategies for GDM mothers. This study aims to define GDM phenotypes based on in vivo cardio-metabolic profiles and treatment response during pregnancy, utilizing advanced technologies such as continuous glucose profiling and untargeted metabolite profiling. In this proposed 3-year pregnancy cohort study, the investigators will recruit 800 overweight or obese Asian pregnant women in early pregnancy, without a history of diabetes, and follow them through to delivery. The goal of the study is to develop systematic antenatal and postnatal screening, treatment, and intervention guidelines for mothers with GDM.",[65,66,67,34,68,69],"Gestational Diabetes","Pregnancy Related","Pregnancy Complications","Insulin Resistance, Diabetes","Intergenerational Relations",[71],"Pregnancy","2025-05-25",{"date":74,"type":41},"2025-05-28",{"date":76,"type":41},"2022-10-03",{"date":78,"type":23},"2026-07-01",{"name":80,"class":48},"National University Health System, Singapore",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":17,"sex":18,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":5},"100493671","healthy-mums-healthy-babies-multiple-micronutrient-supplementation-in-ethiopia-100493671","NCT05708183","Healthy Mums, Healthy Babies: Multiple Micronutrient Supplementation in Ethiopia","Healthy Mums, Healthy Babies in Ethiopia: a Cluster-randomized Trial to Evaluate the Programme Effectiveness of a Multiple Micronutrient Supplement Delivered to Pregnant Women Through Routine Antenatal Care to Improve Newborn Birthweight","Inclusion Criteria:\n\n* For the primary outcome, mothers who deliver a liveborn child in enrolled health facilities and who are willing\u002Fconsent to participate in the study.\n* For the secondary objectives, all antenatal care staff and women attending for routine antenatal care during the survey periods will be included.\n\nExclusion Criteria:\n\n* For the primary outcome, stillbirths will be excluded. Data for any newborn who subsequently dies while still in the facility will be excluded from all secondary analyses.","15 Years","49 Years",{"count":92,"type":23},25620,"Background: This programme effectiveness study responds to the need for evidence on the effect on birthweight of switching from iron-folic acid supplementation (IFA) to multiple micronutrient supplementation (MMS) as part of routine antenatal care in Ethiopia. A 2019 meta-analysis of trial data reported a mean improvement of 35g in newborn birthweight amongst newborns born to women who took MMS in pregnancy compared to those who took IFA. Responding to this evidence, in 2020 the World Health Organisation updated its global guideline on MMS from 'not recommended' to 'recommended in the context of rigorous research'. The guideline identifies priority research being 'to establish the impact of switching routine antenatal IFA to MMS on important health outcomes, equity, acceptability, feasibility, sustainability and health-care resources in different country settings.' In 2022 the Ministry of Health of Ethiopia (MoH), will change from MMS to IFA in a set of pilot districts. EPHI and LSHTM have been asked to evaluate the effect of this change on mean birthweight and propose the current trial for this purpose.\n\nThe overall aim is to evaluate the programme effectiveness on mean birthweight of providing MMS as part of routine antenatal care, compared to providing IFA.\n\nFindings will support the MoH to make evidence-informed decisions about the large-scale implementation of MMS in Ethiopia and also contribute to the global evidence base on the effectiveness of MMS in a programmatic setting.\n\nMethods: A two-arm cluster randomized trial will be used to estimate the effect of the programme change on mean birthweight, with cost-effectiveness and process evaluations embedded in the trial design.\n\nWomen aged 15-49 who deliver a live born child in a study district health facility (mother\u002Finfant dyads) will be eligible for enrolment in the study.\n\nThe primary outcome measure will be birthweight, recorded in facilities at the time of birth as part of the routine maternity care.\n\nSecondary objectives include costs of providing MMS, acceptability of MMS, adherence to antenatal micronutrient supplementation and implementation challenges.",[34],"2024-12-09",{"date":97,"type":41},"2024-12-12",{"date":99,"type":41},"2023-01-01",{"date":101,"type":23},"2025-08-31",{"name":103,"class":48},"London School of Hygiene and Tropical Medicine",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":4,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":81},"100553530","levels-of-visfatinnampt-in-human-milk-100553530","NCT06487286","Levels of Visfatin\u002FNAMPT in Human Milk","Levels of Visfatin\u002FNAMPT in Human Milk.VISFAMILK","VISFAMILK","Inclusion Criteria:\n\n* Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities\n* Maternal hospitalization\n* Acquisition of the informed consent form signed by the patient\n\nExclusion Criteria:\n\n* Refusal of the patient to participate in the study\n* Presence of hypogalactia or agalactia in the patient","ALL",{"count":114,"type":23},30,"Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic\u002Fpredictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.",[117,34],"Visfatin Levels in Maternal Milk Samples",[119,120,121],"Newborns","Visfatin","Breastfeeding","2024-11-12",{"date":124,"type":41},"2024-11-14",{"date":126,"type":41},"2024-10-24",{"date":128,"type":23},"2025-04-23",{"name":130,"class":48},"Paolo Manzoni Study Group",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":17,"sex":18,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":24,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":81},"100532830","effects-of-monitoring-blood-pressure-during-pregnancy-100532830","NCT06217913","Effects of Monitoring Blood Pressure During Pregnancy","Effects of Monitoring Blood Pressure in High-risk Pregnant Women Using a Wearable Device","Inclusion Criteria:\n\n* Women with a single pregnancy before 12 weeks of pregnancy\n* The presence of any of the following risk factors: age \\> 30 years, a history of eclampsia, a family history of eclampsia, obesity (BMI ≥ 30 Kg\u002Fm2), and a history of gestational hyperglycemia (pregestational type 1 and type 2 diabetes; gestational manifest diabetes and gestational diabetes requiring insulin treatment), preexisting chronic hypertension, kidney disease, and autoimmune diseases such as systemic lupus erythematosus and antiphospholipid syndrome.\n* Signed the informed consent can be continuously followed up.\n* Permanent population living in the study area.\n* All subjects received routine antenatal examination and treatment.\n\nExclusion Criteria:\n\n* Termination of pregnancy before 20 weeks\n* Withdraw from the study\n* Lost visitors","18 Years","60 Years",{"count":141,"type":23},400,[26],"In this study, at least 400 women with high-risk of pregnancy hypertension will use a wearable device to monitor the blood pressure during gestational age from 12 weeks to 28weeks. The observed outcomes including maternal and offspring. Participants were from three hospital including Shanghai Xinhua Hospital, Jiaxing Maternal and Child Health Hospital and Peking University Third Hospital. Pregnant women were randomly divided into control group (routine delivery examination group) and intervention group (routine delivery examination group + use of wearable blood pressure monitoring device group), 200 cases each.",[34,145],"Weight Gain Trajectory","NOT_YET_RECRUITING","2024-01-11",{"date":149,"type":41},"2024-01-23",{"date":151,"type":23},"2024-12-01",{"date":153,"type":23},"2027-06-30",{"name":155,"class":48},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":17,"sex":18,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":24,"phases":167,"briefSummary":168,"conditions":169,"keywords":177,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":81},"100427378","fresh-rx-nhs-2020-100427378","NCT04845230","Fresh RX: NHS 2020","Fresh RX: Nourishing Healthy Starts Clinical Study","Inclusion Criteria:\n\n* Female\n* Pregnant\n* Less than 24 weeks gestation\n* Screening positive to a USDA two-item food insecurity screener (described below)\n* Receiving care through a Missouri Medicaid managed care organization\n* English speaking\n* Age 14-55\n* Missouri resident residing in the following zip codes: 63031, 63033, 63042, 63074, 63114, 63121, 63130, 63132, 63133, 63135, 63136, 63137, 63138, 63140\n\nExclusion Criteria:\n\n* Male\n* Non-pregnant\n* Pregnant, but more than 24 weeks gestation\n* Does not screen positive to a USDA two-item food insecurity screener (described below)\n* Does not receive care through the Home State Health managed care organization\n* Non-English speaking\n* Aged less than 14 or more than 55\n* Does not reside in the following zip codes: 63031, 63033, 63042, 63074, 63114, 63121, 63130, 63132, 63133, 63135, 63136, 63137, 63138, 63140","14 Years","55 Years",{"count":166,"type":23},750,[26],"This study is an evaluation of the Fresh Rx: Nourishing Healthy Starts program administered by Operation Food Search, a St. Louis-based nonprofit organization. The program provides food and nutrition supports to food insecure pregnant women in conjunction with integrative care services in order to improve health and birth outcomes for both the mother and the child. The purpose of this study is to test the efficacy of this approach through a field experiment, and to assess the extent to which these services can provide cost savings to the healthcare system.",[170,34,171,172,173,174,175,176],"Premature Birth","Post Partum Depression","Health Care Utilization","Nutrition Deficiency Due to Insufficient Food","Housing Problems","Fetal Complications","Food Deprivation",[178,179,180,181,182,183,184,185,186],"food insecurity","pregnancy","maternal health","neonatal health","birth outcomes","poverty","health care utilization","field experiment","integrative care","2022-11-27",{"date":189,"type":41},"2022-11-29",{"date":191,"type":41},"2021-08-09",{"date":193,"type":23},"2026-09-15",{"name":195,"class":48},"Washington University School of Medicine"]